A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872

BACKGROUND. Src signaling is markedly upregulated at the invasive glioblastoma (GBM) front following bevacizumab administration. The Src family kinase inhibitor, dasatinib, can effectively block bevacizumab-induced glioma invasion in preclinical models. We hypothesized that combining bevacizumab wit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer
Asıl Yazarlar: Galanis, Evanthia, Anderson, S. Keith, Twohy, Erin L., Carrero, Xiomara W., Dixon, Jesse G., Tran, David Dinh, Jeyapalan, Suriya A., Anderson, Daniel M., Kaufmann, Timothy J., Feathers, Ryan W., Giannini, Caterina, Buckner, Jan C., Anastasiadis, Panos Z., Schiff, David
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788934/
https://ncbi.nlm.nih.gov/pubmed/31290996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32340
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller